Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. SPY
3. USO
4. MSFT
5. COST
6. MU
7. IONS
8. ORCL
9. RMR
10. LEVI

Go back to Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson & Johnson (NYSE: JNJ) Delayed: 259.10 -4.3 (1.63%)
Previous Close $263.40    52 Week High $126.07 
Open $260.63    52 Week Low $94.28 
Day High $263.45    P/E 53.87 
Day Low $258.13    EPS $4.81 
Volume 6,425,716